NVO has been in the news 346% more than usual

NVO has been in the news recently: Novo Nordisk has lowered its 2023 sales growth forecast to 8%-14% due to weak sales of Wegovy in the U.S., resulting in a 25% drop in its shares. The company's revised outlook has also contributed to a decline in Eli Lilly's stock price, as investors reacted to the news.